<DOC>
	<DOCNO>NCT02639559</DOCNO>
	<brief_summary>Current protocol use G-CSF mobilize hematopoietic progenitor cell match sibling volunteer unrelated donor . Unfortunately , process require four six day G-CSF injection associate side effect , notably bone pain rarely splenic rupture . BL-8040 give single SC injection , collection cell occur day BL-8040 administration . This study evaluate safety efficacy novel agent hematopoietic progenitor cell mobilization allogeneic transplantation base follow hypothesis : - Healthy HLA-matched donor receive one injection BL-8040 mobilize sufficient CD34+ cell ( least 2.0 x 10^6 CD34+ cells/kg recipient weight ) follow two leukapheresis collection support hematopoietic cell transplant . - The hematopoietic cell mobilize SC BL-8040 functional result prompt durable hematopoietic engraftment follow transplantation HLA-identical sibling advance hematological malignancy use various non-myeloablative myeloablative conditioning regimen regimens routine GVHD prophylaxis . - If hypothesis 1 2 confirm interim safety analysis data , study continue include recruitment haploidentical donor .</brief_summary>
	<brief_title>Safety Efficacy BL-8040 Mobilization Donor Hematopoietic Stem Cells Allogeneic Transplantation Patients With Advanced Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Inclusion Criteria ( DONOR ) : Age 18 70 year age . ECOG performance status 0 1 . PART 1 : Donor must 5/6 6/6 HLAmatched sibling willing donate PBSC transplant . PART 2 : Donor must 5/6 6/6 HLAmatched sibling 3/6 4/6 HLA haploidentical donor willing donate PBSC transplant . Haploidentical donor allow participate upon investigator decision base data reach 5/6 6/6 HLA match transplant do Part 1 study . Adequate organ function define : serum creatinine within normal limit minimum creatinine clearance ( CrCl ) value ≥ 60 ml/min calculate use Modification Diet Renal Disease ( MDRD ) Study equation AST , ALT total bilirubin ≤ 2x institutional upper limit normal . Women childbearing potential men must agree use adequate contraception two different form , include one barrier method , participation study 2 week follow dose BL8040 . Abstinence acceptable establish preferred contraception subject . Female subject must negative urine serum pregnancy test within 10 day prior take study medication childbearing potential must nonchildbearing potential . If urine test positive confirm negative , serum pregnancy test require . The serum pregnancy test must negative subject eligible . Nonchildbearing potential define : ≥ 45 year age menses &gt; 2 year Amenorrheic &gt; 2 year without hysterectomy oophorectomy FSH value postmenopausal range upon pretrial ( screen ) evaluation Posthysterectomy , oophorectomy , tubal ligation . Able willing comply requirement protocol . Able understand willing sign IRBapproved write informed consent document . Inclusion Criteria ( RECIPIENT ) : Age 18 75 year ECOG performance status 02 ( inclusive ) One follow diagnosis : Acute myelogenous leukemia ( AML ) 1st subsequent remission Acute lymphoblastic leukemia ( ALL ) 1st subsequent remission Chronic myelogenous leukemia ( CML ) chronic accelerate phase NonHodgkin lymphoma ( NHL ) Hodgkin 's disease ( HD ) 2nd great complete remission , partial remission Chronic lymphocytic leukemia ( CLL ) Multiple myeloma ( MM ) Myelodysplastic syndrome ( MDS ) Myeloproliferative neoplasm ( MPN ) exclude primary secondary myelofibrosis Adequate organ function define : creatinine clearance ( CrCl ) value ≥ 60 ml/min MDRD study equation AST , ALT total bilirubin ≤ 2x institutional upper limit normal . Adequate cardiac function leave ventricular ejection fraction ≥ 40 % . Adequate pulmonary function define NO severe symptomatic restrictive obstructive lung disease , formal pulmonary function test show FEV1 ≥50 % predict DLCO ≥ 40 % predict , correct hemoglobin . Female subject must negative urine serum pregnancy test childbearing potential nonchildbearing potential . If urine test positive confirm negative , serum pregnancy test require . The serum pregnancy test must negative subject eligible . Nonchildbearing potential define : *≥ 45 year age menses &gt; 2 year Amenorrheic &gt; 2 year without hysterectomy oophorectomy FSH value postmenopausal range upon pretrial ( screen ) evaluation Posthysterectomy , oophorectomy , tubal ligation . Able understand willing sign IRBapproved write informed consent document . Exclusion Criteria ( DONOR ) : Received investigational agent within 30 day and/or 5 halflives ( investigational agent ) , whichever longer , receive BL8040 . Active HIV hepatitis B C infection Pregnant breastfeeding . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Known allergy hypersensitivity test compound , material , contraindication test product . Any malignancies 2 year prior baseline , exclude : basal cell carcinoma , situ malignancy , lowrisk prostate cancer , cervix cancer curative therapy . A comorbid condition , view investigator , render subject high risk treatment complication . Exclusion Criteria ( RECIPIENT ) : Recipient must receive investigational drug within 30 day start conditioning treatment . Pregnant breastfeeding . Active HIV hepatitis B C infection . Any medical condition , opinion clinical investigator , would interfere evaluation patient . Subjects clinically significant unstable medical surgical condition condition wellcontrolled allow medication permit study protocol would preclude safe complete study participation , determine medical history , physical examination , ECG , laboratory test , chestXray accord investigator 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>